Chua Ramon, Setzer Shannon, Govindarajan Baskaran, Sexton Debbie, Cohen Cynthia, Arbiser Jack L
Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
J Am Acad Dermatol. 2009 May;60(5):758-66. doi: 10.1016/j.jaad.2009.01.018.
Maspin is a serine protease inhibitor that is thought of as a tumor suppressor because of observations that loss of maspin expression in breast, prostate, and oral cancer is associated with poor prognosis. In addition, maspin may function as an inhibitor of angiogenesis. However, it has been correlated with malignant behavior in pancreatic and ovarian cancer. The role of maspin in malignant melanoma (MM) has not yet been systematically examined.
We aimed to examine the immunohistochemical expression of maspin and several proangiogenic factors (vascular endothelial growth factor, transforming growth factor-beta, alphaVbeta3 integrin, cyclooxygenase-2, and CD44) in MM and correlate each to angiogenesis, tumor thickness, and outcome.
In all, 77 formalin-fixed, paraffin-embedded MM samples were immunostained for maspin and other proangiogenic factors (vascular endothelial growth factor, transforming growth factor-beta, alphaVbeta3 integrin, cyclooxygenase-2, and CD44) and were correlated with angiogenesis as mean microvessel density. Three normal-appearing skin samples and 10 nevi were also immunostained for maspin. Breslow thickness, Clark level, clinical stage, and follow-up information were obtained for outcome analysis.
Immunohistochemical analysis revealed strong nuclear melanocytic maspin expression in all 10 nevi (half of which were dysplastic) but none in melanocytes from 3 normal-appearing skin samples. Strong nuclear maspin staining was demonstrated in 78% of radial phase melanoma and 46% of vertical growth phase melanoma. In addition, there was a significant inverse relationship between maspin and microvessel density (P = .018) and tumor thickness greater than 0.76 mm (P = .007), indicating that maspin is expressed in thinner tumors with less angiogenesis. Conversely, vascular endothelial growth factor expression, Clark level, and Breslow thickness all significantly correlated with microvessel density (P = .047, P = .027, and P = .011, respectively). Cyclooxygenase-2 expression significantly correlated with thicker tumors (P = .006) but not with angiogenesis (P = .714). In addition, Clark level, Breslow thickness, and stage were all significant predictors of overall survival (P < .001, P = .005, and P < .001, respectively).
This study represents a single institution.
These results demonstrate maspin expression in nevi and radial growth phase melanoma, but this expression seems to be lost in the transition from radial growth phase to vertical growth phase melanoma. In addition, maspin is correlated with decreased angiogenesis and tumor thickness less than 0.76 mm in MM. These results indicate maspin may function as a tumor suppressor in MM.
Maspin是一种丝氨酸蛋白酶抑制剂,由于观察到其在乳腺癌、前列腺癌和口腔癌中的表达缺失与预后不良相关,因此被认为是一种肿瘤抑制因子。此外,Maspin可能作为血管生成的抑制剂发挥作用。然而,它与胰腺癌和卵巢癌的恶性行为相关。Maspin在恶性黑色素瘤(MM)中的作用尚未得到系统研究。
我们旨在检测MM中Maspin和几种促血管生成因子(血管内皮生长因子、转化生长因子-β、αVβ3整合素、环氧合酶-2和CD44)的免疫组化表达,并将其与血管生成、肿瘤厚度和预后相关联。
总共77个福尔马林固定、石蜡包埋的MM样本进行了Maspin和其他促血管生成因子(血管内皮生长因子、转化生长因子-β、αVβ3整合素、环氧合酶-2和CD44)的免疫染色,并与作为平均微血管密度的血管生成相关联。还对3个外观正常的皮肤样本和10个痣进行了Maspin免疫染色。获取Breslow厚度、Clark分级、临床分期和随访信息用于预后分析。
免疫组化分析显示,所有10个痣中黑素细胞均有强烈的核Maspin表达(其中一半为发育异常痣),但3个外观正常的皮肤样本中的黑素细胞均无表达。78%的放射状生长期黑色素瘤和46%的垂直生长期黑色素瘤显示有强烈的核Maspin染色。此外,Maspin与微血管密度(P = 0.018)和厚度大于0.76 mm的肿瘤(P = 0.007)之间存在显著负相关,表明Maspin在血管生成较少的较薄肿瘤中表达。相反,血管内皮生长因子表达、Clark分级和Breslow厚度均与微血管密度显著相关(分别为P = 0.047、P = 0.027和P = 0.011)。环氧合酶-2表达与较厚的肿瘤显著相关(P = 0.006),但与血管生成无关(P = 0.714)。此外,Clark分级、Breslow厚度和分期均是总生存的显著预测因素(分别为P < 0.001、P = 0.005和P < 0.001)。
本研究为单机构研究。
这些结果表明痣和放射状生长期黑色素瘤中有Maspin表达,但这种表达在从放射状生长期向垂直生长期黑色素瘤的转变中似乎丧失。此外,MM中Maspin与血管生成减少和厚度小于0.76 mm的肿瘤相关。这些结果表明Maspin在MM中可能作为肿瘤抑制因子发挥作用。